Pralsetinib is a prescription medicine used to treat adults with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic feature (an abnormal “RET” gene). Pralsetinib is a type of targeted therapy called a kinase inhibitor. It works by blocking some of the proteins that can help cancer cells grow and spread.
Pralsetinib is a targeted therapy medication used to treat specific types of lung cancer. Here's a breakdown of its key aspects:
Main Function:
- Targets Specific Lung Cancers: Pralsetinib is designed to target cancers with alterations (mutations) in a gene called RET. RET alterations are not common in lung cancer, but they can be a significant driver of tumor growth in some cases. Pralsetinib works by blocking the abnormal activity of the RET protein, helping to slow or stop cancer cell growth.
Type of Medication:
- Tyrosine Kinase Inhibitor (TKI): Pralsetinib falls under the class of medications called tyrosine kinase inhibitors (TKIs). TKIs block specific enzymes (kinases) needed for the growth and survival of cancer cells.
Applications:
- RET-Mutant Non-Small Cell Lung Cancer (NSCLC): Pralsetinib is approved for the treatment of adults with RET-mutant advanced NSCLC. NSCLC is the most common type of lung cancer.
Administration:
- Oral Tablets: Pralsetinib comes in tablet form and is taken orally, typically once daily with or without food.
Important Considerations:
- Targeted Therapy: Pralsetinib is a targeted therapy medication, meaning it specifically targets the RET alterations in cancer cells. This can offer a more precise approach to treatment compared to traditional chemotherapy drugs.
- Genetic Testing Required: Pralsetinib is only beneficial for patients whose tumors have been confirmed to have RET mutations. Genetic testing is necessary to determine if someone is a candidate for this medication.
- Potential Side Effects: Like most medications, Pralsetinib can cause side effects. Common ones include fatigue, nausea, diarrhea, and headache. More serious side effects, though uncommon, can also occur. It's crucial to discuss potential risks and benefits with your doctor before starting Pralsetinib.
- Monitoring: Regular monitoring by your doctor is necessary while taking Pralsetinib. This may involve blood tests to assess side effects and tumor response to treatment.
Overall:
Pralsetinib provides a valuable treatment option for patients with RET-positive NSCLC. However, it's essential to understand its targeted nature, the need for genetic testing, and the potential side effects.